Quelques intervenants participants au colloque ATHS 2019 :
Marc Auriacombe (Bordeaux)
Marc Auriacombe is a Professor of Psychiatry and Addiction medicine at the Medical School of the University of Bordeaux, Bordeaux, France and an Adjunct Associate Professor of Psychiatry at the University of Pennsylvania, Philadelphia, PA., USA. He is the director of the
addiction research team at CNRS USR 3413 Sanpsy and medical director of the Addiction Treatment Services of the Charles Perrens Hospital in Bordeaux, France. He is the principal senior investigator of an integrated addiction research program funded by French national and
European funds. With Jean-Pierre Daulouède and Jean Tignol he has contributed to introduce the Addiction Severity Index in France in 1989. Marc Auriacombe was awarded the EUROPAD Award 2002 « Chimera d’Argento » « Dedicated to all those who dream of a better
world for drug addicts » and has published over 200 papers in research and educational journals and books in English, French and Spanish.
Nicolas Authier (Clermont-Ferrand)
Inserm 1107, Université Clermont Auvergne, CHU Clermont-Ferrand. Professeur des universités et praticien hospitalier, chef du Service de Pharmacologie Médicale et du Centre d’Evaluation et de Traitement de la Douleur du CHU de Clermont-Ferrand (www.pharmacologie-clermont.fr). Médecin psychiatre de formation spécialisé en pharmacologie et addictologie, il s’occupe notamment de la consultation pharmacodépendance et du centre addictovigilance(www.addictauvergne.fr). Ses travaux de recherche, au sein de l’UMR INSERM 1107 NEURO-DOL, se focalisent actuellement sur les liens entre douleur et addiction mais aussi sur l’optimisation du bénéfice-risque des antalgiques et plus particulièrement sur le mésusage des médicaments opioïdes chez les patients douloureux et les patients dépendants ainsi que sur les stratégies de sevrage en opioïdes.Il développe notamment pour cela des études cliniques et pharmaco-épidémiologiques sur bases de données centrées sur les opioïdes (antalgiques, substitution). Il est président de la commission des stupéfiants et psychotropes de l’ANSM depuis février 2016. En 2017, il créé l’Observatoire Français des Médicaments Antalgiques (OFMA).
Amine Benyamina (Villejuif)
Amine Benyamina est Psychiatre Addictologue à l’Hôpital Universitaire Paul Brousse à Villejuif, il est également Professeur des Universités à la Faculté de Médecine Paris XI.Il est responsable de plusieurs Diplômes Universitaires nationaux et internationaux.
Il est responsable du Centre de Recherche et de Traitement des Addictions. Il est Président de la Fédération Française d’Addictologie (FFA). Il est Président de l’Association Franco-Maghrébine de Psychiatrie. Il est rédacteur en chef de la revue Alcoologie et Addictologie et administrateur de la Société Française d’Alcoologie (SFA),de l’Association Française de Psychiatrie Biologique et Neuropsychopharmacologie (AFPBN). Il est l’auteur d’une cinquantaine d’articles scientifiques référencés traitants des questions de thérapeutique, de biomarqueurs et de comorbidités
psychiatriques et addictives. Il est également l’auteur de nombreux ouvrages à vocation académique et pédagogique et a coordonné plusieurs ouvrages collectifs. Il est également l’auteur d’ouvrages plus grand public traitant des questions d’addiction notamment le cannabis et l’alcool. Il est le fondateur du congrès de l’Albatros, un congrès international d’addictologie qui se tient tous les ans à Paris.
Nicolas Bonnet (Paris)
Docteur en pharmacie, titulaire du master en santé publique de Paris X, j’exerce depuis 1999 dans le domaine de l’addictologie où j’ai pu développer des compétences spécifiques dans la clinique des addictions en milieux institutionnel, associatif, hospitalier et universitaire. Mon parcours professionnel en addictologie m’a permis d’acquérir des compétences dans 3 domaines principaux : la pharmacologie, la veille sanitaire et la pharmacie clinique. J’ai ainsi notamment travaillé à Médecins du Monde comme coordinateur national de la mission analyse des drogues XBT dont les travaux ont amené à la diffusion de la technique d’analyse par chromatographie couche mince, à Apothicom pour la création du Sterifilt ou bien à l’Observatoire français des drogues et toxicomanies au sein du pôle TREND. Je suis actuellement directeur du RESPADD, Réseau des établissements de santé pour la prévention des addictions et responsable de la consultation jeunes consommateurs de l’hôpital Pitié-Salpêtrière à Paris. Le RESPADD constitue le plus important réseau d’établissements de santé en Europe soit plus de 800 établissements de santé adhérents mobilisés et actifs dans la prévention et la prise en charge des conduites addictives. Il est à l’origine de la stratégie « Lieu de santé sans tabac » et du réseau « Lieu de santé promoteur de santé ». Investi de longue date en réduction des risques dans le secteur associatif, j’assure actuellement la présidence du CAARUD Proses à Montreuil. Enfin, après avoir été secrétaire général de l’Association française pour la réduction des risques je siège aujourd’hui au bureau du collectif Galilée.
Sandra Comer (New York)
Sandra D. Comer, Ph.D. Comer is Professor of Neurobiology in the Department of Psychiatry at Columbia University. She received her BS at Vanderbilt University and PhD at the University of Michigan for her research on the effects of abused drugs using preclinical models. Dr. Comer’s current research focus is on the clinical testing of medications for treating opioid use disorder, methods to maximize the use of naloxone by opioid users, and evaluations of the comparative abuse liability of prescribed pain medications. Dr. Comer recently served as President of the College on Problems of Drug Dependence, the longest standing scholarly society in the U.S. devoted to research on substance use disorders, and currently is the Public Policy Officer for CPDD. Dr. Comer recently joined the Expert Advisory Panel on Drug Dependence for the WHO and has over 140 publications on substance use disorders.
Maurice Dematteis (Grenoble)
Neurologue, Professeur d’Addictologie et de Pharmacologie, fondateur et responsable de la Clinique Universitaire d’Addictologie du CHU de Grenoble. Assesseur du Doyen à la Faculté de Médecine de Grenoble, il y a réformé les études du premier cycle des études médicales et a contribué à développer et à structurer l’enseignement de l’Addictologie dans sa Faculté et son interrégion. Il a participé à différentes études muticentriques nationales, aux différents groupes de travail nationaux (alcool, antalgiques morphiniques, substitution opiacée, nouveaux produits de synthèse / nouvelles substances psychoactives) et à la rédaction des dernières recommandations en Alcoologie. De par sa formation, il s’intéresse particulièrement aux addictions médicamenteuses, à leur caractérisation et à leur prise en charge. Enfin, il a développé le programme ETAPE, programme novateur inspiré de l’éducation thérapeutique pour l’entourage de consommateurs.
Don C Des Jarlais (New York)
Don C. Des Jarlais, Ph.D. is Director of Research for the Baron Edmond de Rothschild Chemical Dependency Institute at Beth Israel Medical Center, a Senior Research Fellow with the National Development and Research Institutes, Inc. and a Guest Investigator at Rockefeller University in New York. He began his research on AIDS in 1982. As a leader in the fields of AIDS and injecting drug use, Dr. Des Jarlais has published extensively on these topics including papers in the New England Journal of Medicine, the Journal of the American Medical Association, Science and Nature. He has been particularly active in international research, having collaborated on studies in twenty-five different countries. He serves as a consultant to various institutions, including the Centers for Disease Control and Prevention, the National Institute on Drug Abuse, the National Academy of Sciences and the World Health Organization. He is a former commissioner for the US National Commission on AIDS, and is currently a Core Group Member of the UNAIDS Reference Group on HIV and Injecting Drug Use. In 2010 Dr. Des Jarlais was elected to the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) Scientific Advisory Board (SAB).
Mélina Fatseas (Bordeaux)
Professeur des universités et praticien hospitalier, chef du Pôle Addictologie du CHU de Bordeaux, Mélina Fatseas est psychiatre addictologue. Ses travaux de recherche au sein de l’équipe Neuroimagerie et Cognition humaine (INCIA, CNRS UMR 5287) portent sur les marqueurs de vulnérabilité dans les addictions et plus particulièrement sur le craving et ses déterminants environnementaux, cognitifs et émotionnels. Ses travaux visent également à optimiser les prises en charge thérapeutiques en développant des approches personnalisées ciblées sur les marqueurs de vulnérabilité.
Andrew Freedman (Denver)
Andrew brings vast experience from his three years as the State of Colorado’s first Director of Cannabis Coordination. During this time, he developed distinctive experience effectively implementing voter-mandated legalized adult-use and medical cannabis while protecting public health, maintaining public safety, and keeping cannabis out of the hands of children.
Andrew’s role in developing a successful operating model for cannabis regulation and stakeholder collaboration was identified as one of the reasons for the State of Colorado’s success in implementing adult-use cannabis legalization by the Brookings Institution. (Lire la suite)
Mark Greenwald (Detroit)
Mark Greenwald, Ph.D. is Professor (tenured), Associate Chair for Research and Director of the Substance Abuse Research Division in the Department of Psychiatry and Behavioral Neurosciences (with joint appointment in the Department of Pharmacy Practice) at Wayne State University in Detroit, Michigan.His research focuses on multiple determinants of persistent drug use,leveraging biomarkers and clinical assessments to advance ourunderstanding of substance use disorders,and developing novel medication and behavioural treatments—primarily focused onopioids. He has published more than 100 research papers, reviews and book chapters, and more than 200 research abstracts. His research has received continuous funding from the US National Institutes of Health(NIH) since 1996. He has served on multiple national and international grant review committees and formerly chairedboth an NIH anda US VeteransAffairs grant review committee. He collaborates with industry partners involved in developing anti-addiction treatments. He is Past-President of the American Psychological Association Division 28andhas served on many national, state and local committees, and advisory boards, related to substance use disorders. He is a leader in interdisciplinary research and education, mentoring junior faculty, postdoctoral fellows, medical students and graduate students on topics related to substance use disorders.
Margaret Haney (New York)
Dr. Margaret (Meg) Haney is a Professor of Neurobiology (in Psychiatry) at the Columbia University Irving Medical Center. As the Director of the Cannabis Research Laboratory and Co-Director of the Substance Use Research Center, Dr. Haney is internationally recognized for her expertise in cannabis and cannabinoids. Her current work focusses on (1) conducting placebo-controlled studies testing the efficacy of potential treatment medications for Cannabis Use Disorder, and (2) testing the potential therapeutic effects of cannabis and its constituents for a range of indications, including appetite-enhancement, experimental pain, chemotherapy-induced neuropathy, and Obsessive-Compulsive Disorder. Dr. Haney’s research has been continuously supported by the National Institute of Health since 1999. She has authored more than 140 articles in peer-reviewed journals, 11 book chapters, is an Associate Editor for Cannabis and Cannabinoid Research, is an Advisory Editor for Psychopharmacology, and recently co-edited Neuropsychopharmacology Reviews 2018, Cannabis and Cannabinoids: From Synapse to Society. Dr. Haney is a longstanding participant in NIH review groups, is a Fellow at the American College of Neuropsychopharmacology, and the recent past President of the College on Problems of Drug Dependence.
Marie Jauffret-Roustide (Paris)
Marie Jauffret-Roustide is a Research Fellow, Sociologist at the French National Institute of Health and Medical Research (Inserm) in France, Paris. She is the leader of an international comparative research on the history of harm reduction between France and North America. She proposes to analyze three representative contemporary drug policy issues affecting and partially North America and Europe (France) : the history of opioid substitutive treatments, the opioid overdose crisis, and the controversy on drug consumption rooms. Marie Jauffret-Roustide’s research focuses on drug policy and harm reduction paradigm, ethnicity and gender issues, laws, and regulations, structural inequalities in health and social policies, and patient groups’ and users’ involvement in drug policy changes, including analyses of the biomedicalization process of addiction. (Lire la suite)
Yifrah Kaminer (Farmington)
Yifrah Kaminer M.D., M.B.A.
Professor of Psychiatry* & Pediatrics**
Alcohol Research Ctr*& Pediatric Injury Prevention Ctr**
University of Connecticut School of Medicine
195 Farmington Avenue, Farmington, CT 06030-6326, USA
Kaminer@uchc.edu
Dr. Kaminer received his M.D. from Sackler School of Medicine, Tel-Aviv Univ. Israel.
1984: Completed a combined General and Child & Adolescent Psychiatry residency at TAU. (Lire la suite)
Joshua LEE (New York)
Joshua D. Lee MD, MSc is an Associate Professor of Population Health and Medicine/General Internal Medicine and Clinical Innovation at the NYU School of Medicine and Director of the NYU Fellowship in Addiction Medicine. He is a clinician researcher focused on addiction pharmacotherapies in primary care as and criminal justice populations. He has conducted multiple NIH clinical trials examining the use of naltrexone and buprenorphine opioid and alcohol treatments in community criminal justice involved adults, at release from jail, and within community primary care settings.
Frances Levin (New York)
Areas of Expertise / Conditions Treated Addiction Psychiatry, Addictive Disorders, Adult ADHD, Clinical Research, Substance Use.
Academic Appointments Kennedy-Leavy Professor of Psychiatry in the Division of Substance Abuse at CUMC. Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Clinical Psychiatry at Columbia University and Chief of the Division on Substance Use, and Director of the Addiction Psychiatry Fellowship Program at New York Presbyterian Hospital. Dr. Levin graduated from Cornell University Medical College and completed her psychiatric residency at the New York Hospital-Payne Whitney Clinic. (Lire la suite)
Walter Ling (Los Angeles)
Walter Ling, M.D., is Professor of Psychiatry and Founding Director of the Integrated Substance Abuse Programs (ISAP) at UCLA, one of the foremost substance abuse research groups in the United States and worldwide. He is board certified in neurology and psychiatry, is active in research and clinical work, and has been listed in « Best Doctors in America, » « Best Doctors in the West, » and « Best Doctors in Los Angeles. » Dr. Ling’s research in pharmacotherapy for opioid addiction provided pivotal information for the approval of LAAM, naltrexone, and buprenorphine. His research projects have included investigations of medications for the treatment of opioid, cocaine, methamphetamine, and cannabis use disorders, opioid-induced hyperalgesia, and treatment of pain in opioid-maintained patients. Dr. Ling has extended ISAP’s research beyond the United States to Asia and the Middle East, and he has led or participated in international training efforts in 15 countries to advance addiction medicine and addiction research. As Principal Investigator of the Pacific Region Node of the NIDA Clinical Trial Network (CTN), Dr. Ling most recently completed a multi-site clinical trial using a medication combination of extended-release naltrexone with daily bupropion for the treatment of methamphetamine use disorders. This project used a novel stepped approach for and enhanced methods for confirming medication adherence including daily dosing videos captured with Smartphones sent by study participants to the study team. Dr. Ling’s current and future research projects will continue to examine potential and promising methods for the treatment of substance use disorders.
Michelle Lofwall (Lexington)
Michelle Lofwall MD is a Professor of Behavioral Science and Psychiatry and the Bell Alcohol and Addictions Chair at the University of Kentucky Center on Drug and Alcohol Research. She is the medical director of the First Bridge outpatient opioid use disorder (OUD) treatment clinic that provides comprehensive care to patients discharging from the emergency room and inpatient medical/surgical services. Herclinical research has been funded by the National Institutes of Health and industry with a focuson OUD, including medication development of long-acting buprenorphine implants and weekly and monthly buprenorphine injections.She was as an expert panel member on SAMHSA’s newly published Substance Treatment Improvement Protocol (TIP 63) for Medication Treatment of OUD, a board member of the American Society of Addiction Medicine, an invited speaker to the National Academy of Medicine and recipient of several medical student teaching and mentorship awards.
Icro Maremmani (Pise)
Icro Maremmani, MD graduated at the Medical School of the University of Pisa and specialized in Psychiatry cum laude at the University of Pisa. At present he is “Qualified full professor of Psychiatry” and Professor of Addiction Medicine at the University of Pisa, Italy. His expertise field is agonist opioid treatment of heroin addicts, especially patients with dual disorders. He is founding member and Past President of Italian Society of Addiction Medicine (SITD)and Founding member and President of the European Opiate Addiction Treatment Association – EUROPAD. He is Founding President of World Federation for the Treatment of Opioid Dependence (WFTOD), NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC), based in New York, NY, USA.He is founding member and general secretary of the World Association on Dual Disorders (WADD). He received Dole and Nyswander Award in 1994; Chimera Career Award in2004, SEPD Award in 2015, and ISAM fellowship award in 2016. He serves also as editor in chief of Heroin Addiction and Related Clinical Problems and academic editor of IJERPH and JCM.Up to present has published more than 600 scientific and professional papers and 20 books. Presently taking part, as active member, more than 450 scientific meetings.
Fadi Meroueh (Villeneuve-Lès-Maguelonne)
Le Dr Fadi Meroueh est praticien hospitalier addictologue, chef de service de l’Unité Sanitaire de la Maison d’Arrêt de Villeneuve les Maguelone, rattaché au Pôle urgences du CHRU de Montpellier. Il assure aussi des vacations au CSAPA Arc en Ciel à Montpellier où il assure une consultation dédiée à la prise en charge de l’hépatite C chez les personnes vivant avec une addiction et dans le Service d’Hépatologie CHU de Montpellier. Il est Expert consultant dans divers organismes nationaux (sidaction) et européens (emcdda, ecdc,…), vice président de la fédération européenne d’HWB (HealthWithoutBarriers)
Ivan Montoya (Bethesda)
Dr. Montoya is the Deputy Director of the Division of Pharmacotherapies and Medical Consequences (DPMC) and Senior Medical Officer at the National Institute on Drug Abuse (NIDA). He received a Doctor in Medicine degree from the University of Antioquia (Colombia) and a Masters in Public Health from The Johns Hopkins School of Public Health. He completed residency training in Psychiatry at the University of Antioquia and the Johns Hopkins University. He has been a Fulbright-Hubert H. Humphrey Fellow at The Johns Hopkins School of Public Health, Visiting Fellow at the Intramural Research Program of NIDA, Director of the Practice Research Network of the American Psychiatric Association, and consultant for the World Health Organization. He has published extensively in the areas of etiology, prevention, treatment (pharmacological and non-pharmacological), and medical consequences of drug abuse.
Mickael Naassila (Amiens)
Mickaël Naassila, Professor of physiologie at the University of Picardie Jules Verne (Amiens, France) and director of the INSERM UMR 1247 research unit (Research Group on Alcohol& Pharmacodependences – GRAP – https://grap.u-picardie.fr). President of the French Society of AlcohologySFA – https://www.sfalcoologie.asso.fr and vice-presidentof the French Federation of addictology FFA – http://www.addictologie.org – President of the 2019 meeting of the European Society on Biomedical Research on Alcoholism (ESBRA) ( https://www.esbra.com, Lille Grand Palais September 21-24th 2019 – http://esbra2019.org). Head of the Addictology University diploma of Amiens University (https://bit.ly/1Pnn9DH ). Partner of the european research project PsiAlc ANR ERA-NET Neuron 2019-2022 – https://www.psialc.org, Preclinical Phase II Testing of Psilocybin in Alcohol Addiction and Epigenetic and Neuroimaging Studies on the Mode of Action.
Vijay R Nadipelli (Richmond)
Vijay Nadipelli, BPharm, MS, is the Head of Global Health Economics & Outcomes Research at Indivior Inc., North Chesterfield, Virginia, USA, a global specialty pharmaceutical company with a mission to discover and develop innovative medications that help transform the lives of patients with addiction and co-occurring disorders. In his current role, Mr. Nadipelli leads health outcomes research and scientific communications to inform and guide access to addiction treatments with a focus on quality and cost of care, with the ultimate goal of improving population health. (Lire la suite)
Milton Romani (Montevideo)
Embajador Milton Romani Gerner: Licenciado en Psicología. Docente de Psicopatología de la Universidad de la República Oriental del Uruguay. Secretario General de Junta Nacional de Drogas de la Presidencia de la República (2005-2011/2015-2016) Uruguay. Embajador Itinerante para Drogas y DDHH. Representante Permanente de Uruguay ante OEA (2012-2014). Representante de Uruguay en: Comisión de Estupefacientes de NNUU, Comisión Interamericana contra el Abuso de Drogas CICAD-OEA, Reunión Especializada de Autoridades de Aplicación en Materia de Drogas del MERCOSUR (RED), Consejo Suramericano para Problema Mundial de Drogas de UNASUR. Jefe de Delegación de Uruguay en la Sesión Especial de la Asamblea General de Naciones Unidas (UNGASS 2016)
Carlos Roncero (Salamanca)
Carlos Roncero MD. Ph D. was graduate as doctor in the University of Valladolid and as a Psychologist in the UNED (Madrid). He was trained as Psychiatrist and Doctorate in the Rovirai Virgil University of Tarragona. He is a psychiatrist specializing in drug dependence and dual diagnosis. He is professor in the Department of Psychiatry of the Universidad de Salamanca (Spain) where he teaches psychiatry in the position of Associate Lecturer. He has taught numerous courses and lectures for pre- and post-graduate university students, doctors in training, psychiatrists, psychologist and general practitioners in Europe, Latinoamerica, USA and Africa. He has also collaborated with international agencies, task force, committees and societies such as the WPA, WFSBP, APAL, OEA and CELAD. (Lire la suite)
Bernard P. Roques (Paris)
Bernard P. Roques learned degrees in pharmacology at Paris University and a PhD in physical chemistry at the EcolePolytechnique. Professor of Pharmacochemistry at Univ. Paris V and Director of an unit CNRS/INSERM (1976-2001). His research spans areas such as 1) DNA poly-intercalators; 2) metallopeptidase inhibitors active in pain treatment and cardiovascular domain with creation of start-up such as Pharmaleads and Quantum Genomics. He develop drugs such as Tiorfan and anti-diabetic Stagid both on the market. Two of the DENKIs, PL37 and PL265, are now in phase II clinical trials active on diabetic neuropathy. Bernard P. Roques is member of the French and European Academies of Sciences. He has received a great number of international awards and published more than 500 papers in international journals. He organised several international meetings.
Fuschia Serre (Bordeaux)
Fuschia Serre graduated with a Master degree in Neurosciences and a PhD in Psychology from the University of Bordeaux, France. She is Research Engineer and clinical research coordinator at Addiction research team of Sanpsy CNRS USR 3413 at University of Bordeaux. Her research interests cover issues of assessments of addiction related behavior with a special interest in the Ecological Momentary Assessment (EMA) methods. Her research topic is related to predictors of relapse with a special focus on craving and its behavioral correlates in human models
Christian Sueur (Lyon)
Psychiatre, praticien hospitalier, chercheur depuis le début des années 1980 sur les questions liées aux usages des drogues, et en particulier, sur l’usage thérapeutiques des substances cannabinoides, et psychédéliques, en psychiatrie. A travaillé au C.S.S.T. de l’Association Abbaye (1982), puis au Centre Saint Germain des Prés (1991), puis au Centre Méthadone de Médecins du Monde (1994), responsable durant les années 90 de l’Antenne Toxicomanie de la Maison d’Arrêt de Fleury Mérogis, (initiateur des Traitements de Substitutions aux Opiacés dans les prisons françaises (1991-2000)), co-fondateur des Missions Raves de Médecins Du Monde (1996-1999), membre du Comité scientifique de l’OFDT lors de la mise en place des systèmes TREND et SINTES (1998-1999) en faveur de l’analyse des drogues de synthèse (ecstasy…) et de la Réduction des Risques dans les Évènements Festifs Techno, Responsable de Mission de MDM en Tchétchénie (1995-1998), puis Praticien hospitalier en Guadeloupe (CHU Pointe à Pitre 2000-2006), puis Responsable du Service de Pédopsychiatrie du Centre Hospitalier de Tahiti (2007-2017). Depuis 2018, pédopsychiatre au Centre Hospitalier du Vinatier, à Lyon. Membre du MAPS depuis 1998, et de l’IACM depuis 2002, et Président fondateur du GRECC, février 2018.
Reem Smoum-Jaouni (The Hebrew University of Jerusalem)
Dr. Reem Smoum-Jaouni, received her Ph.D. in Organic and Medicinal Chemistry from the School of Pharmacy, The Hebrew University of Jerusalem. She completed her Postdoctoral Studies in Cannabinoid Research at the Faculty of Dental Sciences and Institute for Drug Research, Faculty of Medicine at The Hebrew University. She is currently an Associate Research Scientist at the Institute for Drug Research at the Lab of Prof. Raphael Mechoulam. Dr. Smoum-Jaouni’s unique expertise is in the design and synthesis of novel cannabinoids and endocannabinoids-like compounds and in testing their biological activities and potential use against brain diseases, cancer, inflammation, addiction and osteoporosis. (Lire la suite)
Wim Van Den Brink (Amsterdam)
Wim Van Den Brink (1952) received his medical degree in 1981 from the Free University in Amsterdam. After his psychiatric residency in Groningen (1981-1986), he was a fellow at the Psychiatric Epidemiology Training program at Columbia University in New York. In 1989 he received his PhD degree form the State University of Groningen, the Netherlands. Since 1992 he is full professor of Psychiatry and Addiction at the Academic Medical Center of the University of Amsterdam. He is also the director of the Amsterdam Institute for Addiction Research (AIAR). In 2014 he received the life time achievement award for science from the Netherlands Association of Psychiatry and in 2015 he was granted the status of honorable (Lire la suite)
Roger Weiss (Boston)
Dr. Weiss’ career has focused on treatment and clinical research with substance-dependent patients. He has received numerous NIH grants, including for developing integrated group therapy, an evidence-based treatment for co-occurring bipolar and substance use disorders, and leading a multi-site treatment study of prescription opioid dependence. He has authored over 300 publications, including several books, and was vice chair of the American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders.Dr Weiss was named a member of honor by the Spanish Society for Dual Disorders in 2011, and has received numerous other awards (Lire la suite)